Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis

Manisha Gadgeel, Batool AlQanber, Steven Buck, Jeffrey W. Taub, Yaddanapudi Ravindranath, Süreyya Savaşan

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Children with Down syndrome (DS) are at an increased risk of developing transient abnormal myelopoiesis (TAM) and acute leukemia. Aberrant expression of CD56 has been observed on myeloid leukemic blasts in DS patients. In general, CD56 expression in acute myeloid leukemia (AML) is considered a promoter of leukemogenesis. We did a retrospective flow cytometric study to investigate mature myelomonocytic cell CD56 expression patterns in TAM, non-TAM, and leukemia cases with DS. Flow cytometric analysis showed that granulocyte and monocyte aberrant/dysplastic CD56 expression is an inherent characteristic of most DS patients irrespective of the presence of TAM or leukemia. Increased CD56 expression in monocyte and granulocyte populations in DS could be multifactorial; greater expression of RUNX1 secondary to the gene dose effect of trisomy 21 along with the maturational state of the cells are the potential contributors. Unlike AML seen in non-DS patients, CD56 overexpression in DS AML cases does not appear to play a role in leukemogenesis.

Original languageEnglish
Pages (from-to)1695-1700
Number of pages6
JournalAnnals of Hematology
Issue number7
StatePublished - Jul 2021


  • Aberrant CD56 expression
  • Down syndrome
  • Immunophenotyping
  • Neural adhesion molecule 1
  • Transient abnormal myelopoiesis


Dive into the research topics of 'Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis'. Together they form a unique fingerprint.

Cite this